Key Summary
- A clinical trial in HER2-positive metastatic stomach cancer found higher response rates when the drug evorpacept was added to standard treatment and trastuzumab.
- Researchers reported that outcomes were stronger in patients whose tumors remained HER2-positive and also showed high CD47 expression.
- The trial involved 127 patients at 49 institutions in 10 countries.
- The study was published in the journal Nature Medicine.
Main Story
Researchers in South Korea reported clinical evidence that blocking a cancer immune-evasion signal may improve treatment outcomes in metastatic stomach cancer. The study tested a strategy that paired standard anticancer therapy with evorpacept, a drug designed to interfere with the CD47-SIRPα pathway that helps some cancer cells avoid destruction by immune cells.
The trial was conducted in patients with HER2-positive metastatic stomach cancer whose disease had progressed after HER2-targeted treatment. A total of 127 patients were enrolled across 49 institutions in 10 countries. They were randomly assigned to receive either standard chemotherapy plus trastuzumab and evorpacept, or standard chemotherapy plus trastuzumab alone.
According to the hospital, the combination group achieved an objective response rate of 40.3%, compared with 26.6% in the control group. The median duration of response was also longer in the combination group, at 15.7 months versus 7.6 months.
Researchers said the effect was more pronounced in a subset of 48 patients whose tumors remained HER2-positive after prior treatment and also showed high CD47 expression. In that subgroup, the objective response rate was 63.6% in the combination group and 23.1% in the control group. The median duration of response was 25.5 months versus 8.4 months, and median progression-free survival was 19.5 months versus 7.0 months.
The study also noted that patients who did not meet both biomarker conditions did not show a clear added benefit from the combination approach. The team said the findings support the idea of selecting patients based on both HER2 and CD47 status when considering this treatment strategy.
A professor involved in the research said the trial suggests a new anticancer approach that combines a targeted antibody drug with a treatment that blocks a defensive signal used by cancer cells. He added that larger clinical trials would be needed to confirm the results and assess whether the method could develop into precision immunotherapy. He also said the group plans to explore similar strategies using CD47 blockade with antibodies that recognize other cancer targets.
Background
The article explains that some cancer cells exploit the body’s normal “don’t eat me” signaling system to avoid being removed by macrophages. In healthy cells, CD47 on the cell surface binds to the SIRPα receptor on macrophages and sends an inhibitory signal. Some cancer cells increase CD47 expression to strengthen this protection. Evorpacept is described as a drug that disrupts the CD47-SIRPα interaction, while trastuzumab is used to target HER2-positive cancer cells.
Items Requiring Further Verification
- The findings are based on a trial described by the hospital, but the article does not provide the full trial protocol, randomization details, or statistical analysis.
- The claim that the approach could become precision immunotherapy is forward-looking and not yet confirmed by larger studies.
- The article states that the results were published in Nature Medicine, but the specific publication details are not included in the text.
